期刊文献+

Current concepts in the immunohistochemical evaluation of liver tumors 被引量:6

Current concepts in the immunohistochemical evaluation of liver tumors
下载PDF
导出
摘要 Immunohistochemistry often plays an important role in the evaluation of liver tumors. Recent advances have established a classification system for hepatocellular adenomas(HCAs) based on morphology,molecular alterations,and immunohistochemistry. Specifically,loss of liver fatty acid binding protein is seen in HNF1α-inactivated HCA,staining with serum amyloid A isseen in inflammatory HCA,and diffuse staining with glutamine synthetase(GS) is seen in β-catenin activated HCA. A panel of immunohistochemical stains including glypican-3(GPC-3),heat shock protein 70,and GS are useful in distinguishing HCC from non-malignant dysplastic nodules. Immunohistochemistry is also useful to determine whether a liver tumor is of primary hepatocellular or metastatic origin. Recently described markers useful for this purpose include arginase-1,GPC-3,and bile salt export pump. These newer markers may offer superior utility when compared to traditional markers of hepatocellular differentiation such as alpha-fetoprotein,hepatocyte paraffin-1,polyclonal carcinoembryonic antigen,and CD10. This paper will review recent advances in the immunohistochemical evaluation of liver tumors. Immunohistochemistry often plays an important role inthe evaluation of liver tumors. Recent advances haveestablished a classification system for hepatocellularadenomas (HCAs) based on morphology, molecularalterations, and immunohistochemistry. Specifically,loss of liver fatty acid binding protein is seen in HNF1α-inactivated HCA, staining with serum amyloid A isseen in inflammatory HCA, and diffuse staining withglutamine synthetase (GS) is seen in β-catenin activatedHCA. A panel of immunohistochemical stains includingglypican-3 (GPC-3), heat shock protein 70, and GSare useful in distinguishing HCC from non-malignantdysplastic nodules. Immunohistochemistry is alsouseful to determine whether a liver tumor is of primaryhepatocellular or metastatic origin. Recently describedmarkers useful for this purpose include arginase-1,GPC-3, and bile salt export pump. These newer markersmay offer superior utility when compared to traditionalmarkers of hepatocellular differentiation such asalpha-fetoprotein, hepatocyte paraffin-1, polyclonalcarcinoembryonic antigen, and CD10. This paper willreview recent advances in the immunohistochemicalevaluation of liver tumors.
出处 《World Journal of Hepatology》 CAS 2015年第10期1403-1411,共9页 世界肝病学杂志(英文版)(电子版)
关键词 IMMUNOHISTOCHEMISTRY Hepatocellularadenoma FOCAL NODULAR HYPERPLASIA Hepatocellularcarcinoma Immunohistochemistry Hepatocellular adenoma Focal nodular hyperplasia Hepatocellular carcinoma
  • 相关文献

参考文献53

  • 1El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365:1118-1127 [PMID: 21992124 DOI: 10.1056/NEJMra1001683].
  • 2Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecularpathogenesis of focal nodular hyperplasia and hepatocellularadenoma. J Hepatol 2008; 48: 163-170 [PMID: 17997499 DOI:10.16/j.jhep.2007.10.003].
  • 3Wanless IR, Mawdsley C, Adams R. On the pathogenesis of focalnodular hyperplasia of the liver. Hepatology 1985; 5: 1194-1200[PMID: 4065824 DOI: 10.1002/hep.1840050622].
  • 4Nguyen BN, Fléjou JF, Terris B, Belghiti J, Degott C. Focalnodular hyperplasia of the liver: a comprehensive pathologic studyof 305 lesions and recognition of new histologic forms. Am J SurgPathol 1999; 23: 1441-1454 [PMID: 10584697 DOI: 10.1097/00000478-199912000-00001].
  • 5Bioulac-Sage P, Laumonier H, Rullier A, Cubel G, Laurent C,Zucman-Rossi J, Balabaud C. Over-expression of glutaminesynthetase in focal nodular hyperplasia: a novel easy diagnostictool in surgical pathology. Liver Int 2009; 29: 459-465 [PMID:18803590 DOI: 10.1111/j.1478-3231.2008.01849.x].
  • 6Balabaud C, Al-Rabih WR, Chen PJ, Evason K, Ferrell L,Hernandez-Prera JC, Huang SF, Longerich T, Park YN, QuagliaA, Schirmacher P, Sempoux C, Thung SN, Torbenson M, Wee A,Yeh MM, Yeh SH, Le Bail B, Zucman-Rossi J, Bioulac-Sage P.Focal Nodular Hyperplasia and Hepatocellular Adenoma aroundthe World Viewed through the Scope of the ImmunopathologicalClassification. Int J Hepatol 2013; 2013: 268625 [PMID: 23691331DOI: 10.1155/2013/268625].
  • 7Sempoux C, Chang C, Gouw A, Chiche L, Zucman-Rossi J,Balabaud C, Bioulac-Sage P. Benign hepatocellular nodules: whathave we learned using the patho-molecular classification. Clin ResHepatol Gastroenterol 2013; 37: 322-327 [PMID: 23876350 DOI:10.1016/j.clinre.2013.04.008].
  • 8Bioulac-Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, SaCunha A, Rullier A, Cubel G, Couchy G, Imbeaud S, Balabaud C,Zucman-Rossi J. Hepatocellular adenoma subtype classificationusing molecular markers and immunohistochemistry. Hepatology2007; 46: 740-748 [PMID: 17663417 DOI: 10.1002/hep.21743].
  • 9Nault JC, Zucman Rossi J. Molecular classification of hepatocellularadenomas. Int J Hepatol 2013; 2013: 315947 [PMID:23401783 DOI: 10.1155/2013/315947].
  • 10Pilati C, Letouzé E, Nault JC, Imbeaud S, Boulai A, Calderaro J,Poussin K, Franconi A, Couchy G, Morcrette G, Mallet M, TaoujiS, Balabaud C, Terris B, Canal F, Paradis V, Scoazec JY, de MuretA, Guettier C, Bioulac-Sage P, Chevet E, Calvo F, Zucman-RossiJ. Genomic profiling of hepatocellular adenomas reveals recurrentFRK-activating mutations and the mechanisms of malignanttransformation. Cancer Cell 2014; 25: 428-441 [PMID: 24735922DOI: 10.1016/j.ccr.2014.03.005].

同被引文献30

引证文献6

二级引证文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部